Get the Stockscreener App
2.23
1.83%
0.04
After Hours:
2.20
-0.03
-1.35%
Outlook Therapeutics Inc stock is traded at $2.23, with a volume of 1.07M.
It is up +1.83% in the last 24 hours and up +54.86% over the past month.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
See More
Previous Close:
$2.19
Open:
$2.19
24h Volume:
1.07M
Relative Volume:
0.57
Market Cap:
$55.54M
Revenue:
-
Net Income/Loss:
$-51.50M
P/E Ratio:
-0.5575
EPS:
-4
Net Cash Flow:
$-47.10M
1W Performance:
-5.91%
1M Performance:
+54.86%
6M Performance:
-75.08%
1Y Performance:
-70.13%
1-Day Range:
$2.01
$2.23
1-Week Range:
$2.01
$2.325
52-Week Range:
$0.87
$12.85
Outlook Therapeutics Inc Stock (OTLK) Company Profile
Name
Outlook Therapeutics Inc
Sector
Industry
Phone
(609) 619-3990
Address
111 S. WOOD AVENUE, ISELIN, NJ
Compare OTLK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OTLK
Outlook Therapeutics Inc
|
2.23 | 55.54M | 0 | -51.50M | -47.10M | -4.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.00 | 108.68B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
681.58 | 74.90B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
640.52 | 38.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.27 | 31.76B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
111.93 | 26.83B | 3.30B | -501.07M | 1.03B | -2.1146 |
Outlook Therapeutics Inc Stock (OTLK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-24 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Mar-27-24 | Upgrade | BTIG Research | Neutral → Buy |
| Feb-15-24 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Jan-25-24 | Upgrade | Guggenheim | Neutral → Buy |
| Dec-27-23 | Upgrade | CapitalOne | Equal Weight → Overweight |
| Aug-31-23 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Aug-31-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Aug-30-23 | Downgrade | BTIG Research | Buy → Neutral |
| Aug-30-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Aug-30-23 | Downgrade | CapitalOne | Overweight → Equal Weight |
| Aug-30-23 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-13-23 | Initiated | CapitalOne | Overweight |
| Apr-03-23 | Initiated | Guggenheim | Buy |
| Feb-06-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-31-22 | Initiated | BTIG Research | Buy |
| Sep-13-22 | Initiated | Chardan Capital Markets | Buy |
| Sep-11-19 | Initiated | Ladenburg Thalmann | Buy |
| May-16-19 | Initiated | Oppenheimer | Outperform |
| Apr-22-19 | Initiated | Ascendiant Capital Markets | Buy |
View All
Outlook Therapeutics Inc Stock (OTLK) Latest News
Outlook Therapeutics’ (OTLK) “Buy” Rating Reiterated at HC Wainwright - Defense World
Outlook Therapeutics (NASDAQ:OTLK) Earns Buy Rating from Guggenheim - MarketBeat
Layoff Tracker: Notch Therapeutics to ‘Significantly Reduce’ Workforce - BioSpace
Outlook Therapeutics (NASDAQ:OTLK) Receives Buy Rating from HC Wainwright - MarketBeat
Short Interest in Outlook Therapeutics, Inc. (NASDAQ:OTLK) Drops By 17.7% - MarketBeat
Outlook Therapeutics' (OTLK) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
Outlook Therapeutics, Inc. (NASDAQ:OTLK) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Outlook Therapeutics Vision Loss Drug At Par With Novartis Drug - Benzinga
Outlook falls 10% on ONS-5010 update, warrant inducements - MSN
Outlook Therapeutics, Inc. Announces Complete Twelve Week Efficacy and Safety Results of Northeast EIGHT Clinical Trial - Marketscreener.com
Outlook Therapeutics® Announces Complete Twelve Week Efficacy and Safety Results of NORSE EIGHT Clinical Trial - GlobeNewswire
Outlook Therapeutics' ONS-5010 Matches Ranibizumab in 12-Week AMD Trial Results - StockTitan
Analysts Set Outlook Therapeutics, Inc. (NASDAQ:OTLK) Price Target at $32.73 - Defense World
Outlook Therapeutics, Inc. (NASDAQ:OTLK) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Outlook Therapeutics Reports 2024 Financial Results - MSN
Barclays PLC Increases Position in Outlook Therapeutics, Inc. (NASDAQ:OTLK) - Defense World
Geode Capital Management LLC Raises Stake in Outlook Therapeutics, Inc. (NASDAQ:OTLK) - Defense World
OTLKOutlook Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Outlook Therapeutics® Participates in Virtual Investor "What This Means” Segment - The Manila Times
Outlook Therapeutics® Participates in Virtual Investor “What This Means” Segment - GlobeNewswire
Outlook's LYTENAVA Makes History: First Approved Ophthalmic Bevacizumab for Wet AMD in UK - StockTitan
Spartan Delta Corp (SDE-T) QuotePress Release - The Globe and Mail
Outlook Therapeutics (NASDAQ:OTLK) versus Candel Therapeutics (NASDAQ:CADL) Financial Survey - Defense World
State Street Corp Buys 21,201 Shares of Outlook Therapeutics, Inc. (NASDAQ:OTLK) - Defense World
Analysts Offer Predictions for OTLK Q1 Earnings - Defense World
OTLK FY2026 EPS Lifted by Brookline Capital Management - Defense World
Age-related Vision Dysfunction Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Epidemiology, Therapies, Treatment, Companies by DelveInsight - The Globe and Mail
Biotech Alert: Searches spiking for these stocks today - TipRanks
Outlook Therapeutics Stock Surges on Positive Outlook Despite Lo - GuruFocus.com
Outlook Therapeutics Stock Surges on Positive Outlook Despite Loss - Yahoo Finance
Outlook Therapeutics Faces Business Risks from Third-Party Manufacturing Dependencies - MSN
Outlook Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt - Marketscreener.com
Outlook Therapeutics provides ONS-5010/LYTENAVA update - Yahoo Finance
Outlook Therapeutics Inc. (OTLK) reports earnings - Quartz
Outlook Therapeutics Shares Up, Outlines Plans for Macular Degeneration Treatment - Marketscreener.com
Outlook Therapeutics Inc Reports Fiscal Year 2024 EPS of -$4.06, Missing Revenue Estimate of $0.24 Million - GuruFocus.com
Outlook Therapeutics® Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update - The Manila Times
Outlook Therapeutics Secures EU Approval for LYTENAVA™, First Bevacizumab Eye Treatment for Wet AMD - StockTitan
Brokerages Set Outlook Therapeutics, Inc. (NASDAQ:OTLK) PT at $42.34 - Defense World
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Outlook Therapeutic - GuruFocus.com
Charles Schwab Investment Management Inc. Grows Stock Position in Outlook Therapeutics, Inc. (NASDAQ:OTLK) - Defense World
Outlook Therapeutics : Reorganization Form 8 K - Marketscreener.com
Outlook Therapeutics® Streamlines Operations - The Manila Times
Outlook Therapeutics, Inc. Streamlines Operations - Marketscreener.com
Outlook Therapeutics to Cut 23% of Workforce in Push for Lytenava Commercial Launch - MarketWatch
After Golden Cross, Xilio Therapeutics, Inc. (XLO)'s Technical Outlook is Bright - Yahoo Finance
Outlook nabs NICE nod in wet AMD - The Pharma Letter
Outlook Therapeutics® Announces NICE Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD - The Manila Times
Outlook Therapeutics® Announces NICE Recommendation of - GlobeNewswire
Outlook Therapeutics' LYTENAVA Secures Groundbreaking NICE Recommendation for Wet AMD Treatment | OTLKW Stock News - StockTitan
Outlook Therapeutics Inc Stock (OTLK) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.65%
4.62%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):